Pediatric Parenteral Information

Search Another Drug

cycloSPORINE

Immunosuppressive Agents
IWK Hazardous

Reserved/Restricted : Nephrology, Immunology, Gastroenterology, Rheumatology, Dermatology

  • Use only non-PVC bags for mixing and low-sorbing IV administration sets (available from Central Stores)
  • Anaphylactic reaction with first intravenous dose- hypersensitivity reaction orders required.
    • Anaphylaxis most likely occurs due to the IV vehicle polyoxyethylated castor oil rather than the drug itself as the oral product does not possess the same risk. This reaction may present as flushing of face and upper thorax, respiratory distress with dyspnea and wheezing, blood pressure changes and tachycardia
    • Monitor for signs of hypersensitivity reaction for first 30 minutes from start of infusion and frequently thereafter.
Go to Pediatric Drug Dosing Guideline for cycloSPORINE
Administration Information
IV Continuous Infusion
Standard Concentration
2 mg/mL
Monitoring Drug specific monitoring parameters have been approved by the IWK Drugs & Therapeutics Committee. They are assigned to select medications using the <a href='https://www.dir.iwk.nshealth.ca/Content/resources/ParenteralMonitoringGuidelinesRevised.pdf' target='_blank' class='text-warning'>BC Children's Hospital monitoring Levels 1 through 4</a>, these are currently approved <strong>recommendations</strong> for monitoring. An IWK monitoring policy is in development that, once approved, will it guide prescribers and nursing staff through expectations of these monitoring levels. Once the policy is approved, appropriate education and training provided and any necessary equipment is procured, adherence to these drug specific monitoring parameters will be required for all patients receiving medications in the manner described. Until these significant milestones are reached, please continue to follow IWK care area specific practices for monitoring patients.
Blood Pressure and heart rate- every 5 minutes for the initial 15 minutes of infusion

IV Intermittent Infusion
Standard Concentration
2 mg/mL
Administration Duration
02:00 (hh:mm)
Monitoring Drug specific monitoring parameters have been approved by the IWK Drugs & Therapeutics Committee. They are assigned to select medications using the <a href='https://www.dir.iwk.nshealth.ca/Content/resources/ParenteralMonitoringGuidelinesRevised.pdf' target='_blank' class='text-warning'>BC Children's Hospital monitoring Levels 1 through 4</a>, these are currently approved <strong>recommendations</strong> for monitoring. An IWK monitoring policy is in development that, once approved, will it guide prescribers and nursing staff through expectations of these monitoring levels. Once the policy is approved, appropriate education and training provided and any necessary equipment is procured, adherence to these drug specific monitoring parameters will be required for all patients receiving medications in the manner described. Until these significant milestones are reached, please continue to follow IWK care area specific practices for monitoring patients.
Blood Pressure and heart rate- every 5 minutes for the initial 15 minutes of infusion
Comment

Administer consistently via a dedicated lumen to allow therapeutic drug monitoring from opposite lumen

Compatibility Information
Compatible Solutions
5% Dextrose in Water (D5W)
Drug–Drug (Y–Site) or Drug–IV Solution Compatibility
Refer to Micromedex IV Compatibility
Created on August 09, 2019 10:15 AM
Updated on July 09, 2024 04:13 PM

Go Back